Moores Cancer Center

University of California UC San Diego Health

La Jolla, CA
Website
(831) 888-0898Refer Patient

Sorting 2 by

Accepting patients

TRIDENT-1

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Learn more
  • Tyrosine Kinase (TK) Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

Genomically-Guided Treatment Trial in Brain Metastases
Learn more
  • PI3K Inhibitor
  • Tyrosine Kinase (TK) Inhibitor
  • CDK6
  • Phase 2
Get personalized results in 60 seconds
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials